Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2011-12-20 Director's Dealing
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice 2 pages 35.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including the number of shares held before and after the change, the nature of the interest, and transaction details. This is a report of personal share transactions by a company director. The document length is 3685 characters, which is consistent with a detailed director's dealing notice. There is no indication of financial results, management discussion, or other report types. Therefore, this document fits the definition of Director's Dealing (DIRS).
2011-12-20 English
Finance News Network Interview with CEO 2 pages 36.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 19 December 2011, announcing the availability of a Finance News Network interview with the CEO on the company's website. It provides company background, product pipeline information, inherent risks of investment in biotechnology companies, and forward-looking statements. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no capital or financing updates, and no legal proceedings. The document is primarily a media announcement and investor communication rather than a formal financial or regulatory filing. It does not contain the actual report or transcript but rather announces the availability of an interview. Given the content and length (6186 characters), it is not a full financial report or transcript but a regulatory announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and media releases that do not fit other categories.
2011-12-18 English
Change of Director`s Interest Notice 4 pages 61.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report or other category. Therefore, the correct classification is DIRS.
2011-12-12 English
Final Director`s Interest Notice 2 pages 29.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of a director and the director's relevant interests in securities, with all entries marked as NIL. This is a formal notification of a director's personal share transactions or holdings, specifically a final notice upon cessation of directorship. The content matches the definition of Director's Dealing filings, which report personal share transactions or holdings by company directors and executives. The document length is short and focused solely on director interests, with no financial results or other report content. Therefore, the correct classification is Director's Dealing (DIRS).
2011-11-24 English
AGM Chairman`s Address to Shareholders 3 pages 54.0KB
AGM Information Classification · 95% confidence The document is titled 'CHAIRMAN’S ADDRESS TO ANNUAL GENERAL MEETING 24 NOVEMBER 2011' and is presented as a speech given at the 27th Annual General Meeting of Circadian Technologies Limited. It includes introductions of directors and auditors, a summary of the company's strategic progress during the financial year, and outlook statements. The content is typical of a chairman's address delivered at an AGM, focusing on business achievements, strategy, and shareholder communication rather than detailed financial statements or regulatory filings. The document length is 7085 characters, which is consistent with a speech or presentation rather than a full annual report or financial filing. Therefore, the document fits the category of AGM Information (AGM-R).
2011-11-23 English
CEO Presentation to AGM 39 pages 862.1KB
AGM Information Classification · 95% confidence The document is a detailed presentation given at the Annual General Meeting (AGM) of Circadian Technologies Limited on 24 November 2011. It includes corporate snapshots, review of achievements since June 2010, therapeutic development updates, financial summaries, shareholder information, and future milestones. The content is structured as a presentation with slides and detailed business and financial information, typical of materials shared during an AGM. There is no indication that this is a full annual report (10-K), audit report, or earnings release. The presence of the term '2011 AGM PRESENTATION OUTLINE' and the nature of the content strongly indicate this is an AGM Information document, i.e., presentation materials shared during the AGM meeting.
2011-11-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.